BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8976814)

  • 1. Current approaches in cytoprotection: the role of amifostine (Ethyol) in altering and ameliorating toxicities in cancer therapy.
    Bukowski RM
    Eur J Cancer; 1996; 32A Suppl 4():S1. PubMed ID: 8976814
    [No Abstract]   [Full Text] [Related]  

  • 2. The need for cytoprotection.
    Bukowski RM
    Eur J Cancer; 1996; 32A Suppl 4():S2-4. PubMed ID: 8976815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
    Schuchter LM
    Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine and combined-modality therapeutic approaches.
    Mehta MP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
    Capizzi RL
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimal tumor therapy with cytoprotection by ETHYOL (Amifostine). 32nd Annual Session of the American Society of Clinical Oncology in Philadelphia 18-21 May 1996].
    Dtsch Med Wochenschr; 1996 Sep; 121(36 Suppl Fur Die):1-6. PubMed ID: 9417379
    [No Abstract]   [Full Text] [Related]  

  • 7. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amifostine (Ethyol): dosing, administration and patient management guidelines.
    Bukowski RM
    Eur J Cancer; 1996; 32A Suppl 4():S46-9. PubMed ID: 8976823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
    Capizzi RL
    Eur J Cancer; 1996; 32A Suppl 4():S5-16. PubMed ID: 8976816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions in gynecologic cancer.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of amifostine in ovarian cancer.
    Calhoun EA; Bennett CL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):102-7. PubMed ID: 10348268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
    Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Amifostine (ethyol) in the adjunctive treatment of children with acute lymphoblastic leukemia].
    Matysiak M; Stańczak E; Wójtowicz A
    Wiad Lek; 1998; 51 Suppl 4():210-4. PubMed ID: 10731970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future directions in non-small cell lung cancer.
    Schiller JH
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):120-4. PubMed ID: 10348270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current status of toxicity protectants in cancer therapy.
    Schuchter LM; Luginbuhl WE; Meropol NJ
    Semin Oncol; 1992 Dec; 19(6):742-51. PubMed ID: 1334280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
    [No Abstract]   [Full Text] [Related]  

  • 20. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.